Diastereomeric bactericidal effect of Ru(phenanthroline)(2)dipyridophenazine by Mårtensson, Anna et al.
Received: 10 March 2016 Revised: 5 June 2016 Accepted: 21 September 2016DOI 10.1002/chir.22656S HORT COMMUN I CAT I ONDiastereomeric bactericidal effect of Ru(phenanthroline)2
dipyridophenazine
Anna K. F. Mårtensson1 | Mattias Bergentall2 | Valentina Tremaroli2 | Per Lincoln11Department of Chemistry and Chemical
Engineering, Chalmers University of Technology,
Gothenburg, Sweden
2Wallenberg Laboratory and Sahlgrenska Center
for Cardiovascular and Metabolic Research,
Department of Molecular and Clinical Medicine,
Institute of Medicine, University of Gothenburg,
Gothenburg, Sweden
Correspondence
Anna K. F. Mårtensson, Department of Chemistry
and Chemical Engineering, Chalmers University
of Technology, SE‐41296 Gothenburg, Sweden.
Email: marann@chalmers.se
Funding Information
Vetenskapsrådet, VR 2012–1661.Chirality 2016; 28: 713–720ABSTRACT
Metal susceptibility assays and spot plating were used to investigate the antimicro-
bial activity of enantiopure [Ru(phen)2dppz]
2+ (phen =1,10‐phenanthroline and
dppz = dipyrido[3,2‐a:2´,3´‐c]phenazine) and [μ‐bidppz(phen)4Ru2]4+ (bidppz
=11,11´‐bis(dipyrido[3,2‐a:2´,3´‐c]phenazinyl)), on Gram‐negative Escherichia
coli and Gram‐positive Bacillus subtilis as bacterial models. The minimum inhib-
itory concentrations (MIC) and minimum bactericidal concentrations (MBC) were
determined for both complexes: while [μ‐bidppz(phen)4Ru2]4+ only showed a bac-
tericidal effect at the highest concentrations tested, the antimicrobial activity of [Ru
(phen)2dppz]
2+ against B. subtilis was comparable to that of tetracyline. In addition,
the Δ‐enantiomer of [Ru(phen)2dppz]2+ showed a 2‐fold higher bacteriostatic and
bactericidal effect compared to the Λ‐enantiomer. This was in accordance with the
enantiomers relative binding affinity for DNA, thus strongly indicating DNA bind-
ing as the mode of action.
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ruthenium complex1 | INTRODUCTION
The treatment of bacterial infections has become more and
more problematic due to the emergence of multidrug‐resis-
tant pathogens.1,2 With few exceptions, the antibiotics that
are currently available for clinical use all target the same lim-
ited set of bacterial components (the cell wall, the cell mem-
brane, and a few enzymes essential for bacterial growth), thus
increasing the risk for multiresistance.3 Another problem is
that new antibiotics that are coming onto the market are
mostly variants of existing drugs, with the risk that resistance
mechanisms have already developed.4 A noteworthy excep-
tion is the recent discovery of teixobactin, the first member
of a novel class of antibiotics that targets lipid II and lipid
III, both membrane‐anchored cell wall precursors essential
for bacterial cell wall synthesis.5
There are several components in bacteria that have not
been fully explored as potential antimicrobial targets. Bacte-
rial DNA is an attractive antimicrobial target, provided thatwileyonlinelibrary.com/jouspecificity to bacterial cells can be established, as DNA
targeting compounds have the potential risk of also damaging
eukaryotic cells. Actinomycin D, doxorubicin, and daunoru-
bicin are a few examples of DNA binding antimicrobials that
were deemed too cytotoxic for the host6 and were therefore
developed as anticancer treatments.7–9
While a number of reports have analyzed the combina-
tion of transition metals with antibiotics as a way to
increase compounds’ potency against infections
(“metalloantibiotics”),10–12 much fewer studies have tested
the antimicrobial activity of metal complexes alone. Plati-
num‐containing complexes such as cisplatin were shown to
have antimicrobial activity, but were too damaging to
eukaryotic cells, thus only suitable for anticancer treat-
ment.13,14 Ruthenium complexes show less general toxicity
than platinum compounds,15,16 and in particular
ruthenium(II) polypyridyl complexes have several properties
that would make them suitable for antimicrobial treatments
(e.g., water soluble, coordinately saturated, and inert to© 2016 Wiley Periodicals, Inc.rnal/chir 713
714 MÅRTENSSON ET AL.substitution). While the DNA intercalating ability of chiral
ruthenium(II) polypyridyl complexes have been extensively
studied and debated for more than 30 years,17–21 there has
been comparably little interest in testing their antimicrobial
activity despite the pioneering work of Dwyer et al. more than
60 years ago.22,23 This is somewhat surprising, as they are very
stable, readily synthesized, and have strong DNAbinding abil-
ity.24 In addition, their properties are readily modulated by the
peripheral ligands, making it possible to influence DNA bind-
ing and enantioselectivity.20 While the antimicrobial activity
of mononuclear ruthenium(II) polypyridyl complexes has pre-
viously been demonstrated,25,26 to the best of our knowledge
no reported study resolved the complexes in their pure enan-
tiomeric forms. Even fewer studies have been published on
antimicrobial activity in binuclear ruthenium(II) polypyridyl
complexes, with the exception of the work by Li and Keene
et al. 27–33 By coordinating bidentate ligands to the ruthenium
ion two conformations are possible: either a right‐ (Δ) or left‐
handed (Λ) helical structure. The resulting diastereomeric
interactions when bound to a chiral macromolecule, such as
DNA, would assumingly not be identical for both
enantiomers.
In this study we analyzed the antimicrobial activity
of enantiomeric pure [Ru(phen)2dppz]
2+ (Ru‐phen) (phen
=1,10‐phenanthroline and dppz = dipyrido[3,2‐a:2´,3´‐
c]phenazine) and [μ‐bidppz(phen)4Ru2]4+ (biRu‐phen)
(bidppz =11,11´‐bis(dipyrido[3,2‐a:2´,3´‐c]phenazinyl))
(see Scheme 1). Both complexes are well‐established
DNA intercalators and Ru‐phen has already been shown
to not be cytotoxic against HeLa cells.34 As bacterial
models, we used Gram‐negative E. coli and Gram‐positiveSCHEME 1 Structures of (a) Λ‐ (left) and ΔRu‐phen (right), (b) ΛΛbiRu‐
phen, and (c) tetracyclineB. subtilis. As a reference for antimicrobial activity, we
used tetracycline, a broad‐spectrum antibiotic that is active
against both Gram‐positive and Gram‐negative bacteria.2 | MATERIALS AND METHODS
2.1 | Materials
Enantiopure [Ru(phen)2dppz]Cl2 and [μ‐bidppz(phen)4Ru2]
Cl4 used in this study were synthesized as described
elsewhere.35,36 Concentrations were determined
spectrophotometrically using extinction coefficients:
ε440 = 20 000 M−1 cm−1 for Ru‐phen and ε262 = 200
000 M−1 cm−1 for biRu‐phen. Tetracycline hydrochloride
(Sigma‐Aldrich, St Louis, MO), the DNA stain Hoechst
33342 (bis‐benzimidine, Thermofisher, Waltham, MA),
PFA (para‐formaldehyde, Sarstedt, Sweden), SDS (sodium
dodecyl sulfate, Sigma‐Aldrich) and other chemicals were
used without purification. Luria‐Bertani (LB) medium
(10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl), 0.9% saline
solution, 10 mM NaPO4 + 1% LB medium (pH 7), LB agar
plates and phosphate‐buffered saline (PBS) were prepared
at the department of Clinical Microbiology at the
Sahlgrenska University Hospital.2.2 | Bacterial Strains and Culture Conditions
The bacterial strains used in this study were Escherichia coli
DSM 1103 and Bacillus subtilis 168. The strains were pur-
chased from the American Type Culture Collection (ATCC,
Manassas, VA) (ATCC 25922, ATCC 23857) and activated
from freeze‐dried conditions in accordance with the protocol
provided upon delivery. Strains were grown on LB medium
aerobically at 37°C. Stock solutions of the bacterial strains
were prepared from freshly grown bacterial cultures and
stored in 20% glycerol at −70°C.2.3 | Stock Solutions of Tetracycline and Metals
A stock solution of 5 mg/ml tetracycline was prepared in 70%
ethanol and stored protected from light at 8°C. Stock solu-
tions of the complexes were prepared at 5 times the highest
concentration used in the challenge plate (~2000 μM) by
dissolving the chloride salts in autoclaved MilliQ water
(Billerica, MA).2.4 | Metal Susceptibility Assays
Metal susceptibility assays were performed using a method
similar to the MBEC high‐throughput assay as previously
described.37 Frozen stocks of the bacterial strains were
streaked out on agar LB plates to obtain subcultures. After
24 h incubation, a single colony from each strain was col-
lected from the subcultures and suspended in LB medium.
After 24 h incubation, this suspension was diluted 100‐fold
MÅRTENSSON ET AL. 715in LB medium and left to grow an additional 4 h. To ensure
that the bacterial growth was in the exponential phase, optical
density (OD) at 650 nm was measured and the bacterial solu-
tions were spot plated for colony count (OD = 0.3, CFU/
ml = 108, diluted 1:3, used 20 μl so that CFU/well =
2 × 106). Serial dilutions of the ruthenium complexes were
made in LB medium along the length of a sterile 96‐well
microtiter plate (the challenge plate), allowing the first col-
umn to serve as a sterility control and the last column to serve
as a growth control. Each ruthenium complex and tetracy-
cline were tested in triplicate and repeated once to ensure
reproducibility. The challenge plates where incubated for
24 h. To ensure aerobic conditions, a shaking table was used
for incubation of the plates and cultures. A schematic illustra-
tion summarizing the assay protocol can be found in the
Supporting Information (Figure S1).
2.5 | Minimum Inhibitory Concentration and
Minimum Bactericidal Concentration
The MIC is defined as the lowest concentration of a com-
pound that inhibits the visual growth of an organism. We
determined the MIC values by reading the optical density
of the challenge plate at 650 nm (OD650) on a SpektraMax
Plus 384 Microplate Reader (Molecular Devices, MSD Ana-
lytical Technologies, UK). The cellular suspensions in each
row of the challenge plate were then transferred to new sterile
96‐well microtiter plates and diluted 101–108‐fold with
10 mM NaPO4 + 1% LB medium. Twenty‐μl aliquots of each
dilution of each bacterial culture were spot plated in duplicate
onto LB agar plates and incubated for 24 and 48 h. The MBC
is defined as the lowest concentration of an antibiotic
required to kill a particular bacterial strain. The MBC values
were determined by qualitatively scoring the spot plates for
bacterial growth (this was done after 24 and 48 h to ensure
complete eradication of the bacterial cells). The number of




¼ Average colony count
Volume
×dilution (1)2.6 | DNA Binding Emission
Emission spectra were recorded on a Varian Cary Eclipse
Fluorescence spectrophotometer (Agilent Technologies,
Santa Clara, CA). Inoculums of B. subtilis and E. coli in
the exponential phase were incubated overnight (37°C,
120 rpm), either with the enantiomers of Ru‐phen and
biRu‐phen (40 μM) in LB medium or in the medium alone.
After incubation, 1 ml of each bacterial suspension was
centrifuged at 6000 g at room temperature. The pellet was
washed twice in 1× PBS and then resuspended in 1 ml of1× PBS solution. The samples were excited at 440 nm and
emissions were recorded at 500–800 nm.
2.7 | Confocal Microscopy
Confocal microscopy images were obtained with a Leica
TCS SP5 confocal scanning laser microscope (Leica
Microsystems, Germany) controlled by Leica Application
Suite Advanced Fluorescence (LAS AF) 2.6.0.7266 software.
Inoculums of B. subtilis and E. coli in the exponential phase
were incubated with Δ‐ and ΛRu‐phen (40 μM) in LB
medium overnight (37°C, 120 rpm) together with
nonexposed bacterial suspensions as controls. After incuba-
tion, 1 ml of each bacterial suspension was centrifuged at
6000 g at room temperature. The pellet was washed twice
in 1× PBS and then resuspended in 1 ml of 1× PBS solution.
Droplets (40 μl) of each suspension were placed on micros-
copy glass slides (Superfrost, VWR), allowed to adhere for
10 min, and then fixed with 2% PFA in PBS for 10 min.
The slides were washed using PBS solution and the bacteria
were stained with Hoechst 33342 (1:10,000 dilution) for
15 min. The slides were washed one final time with PBS
before mounting using fluorescence mounting medium
(Invitrogen, La Jolla, CA). Samples were viewed using a
63× objective (total magnification 630×) and Ru‐phen
(λex ~ 440 nm, λem ~ 610 nm) was excited using a 458 nm
blue argon laser at 40% intensity. Emission fluorescence of
Ru‐phen was collected at 600–670 nm. Hoechst 33342
(λex ~ 354 nm, λem ~ 486 nm) was excited with an ultraviolet
diode laser and detected using a blue/cyan filter.
2.8 | Nucleotide Leakage
Measurements were performed in accordance with a previous
method described by Henie et al., with minor modifica-
tions.38 Solutions containing bacterial inoculum in the expo-
nential phase treated with biRu‐phen (~300 μM) were filtered
through a 0.22‐μm pore size Millipore Express Millex GP
sterile syringe filter with PES membrane (Merck Millipore,
Germany) at 0, 10, 20, 30, 40, 50, and 60 min; 3% SDS solu-
tion was used as a comparison. Absorption at 260 nm for bac-
terial nucleic acids were measured using a Varian Cary 4000
UV/vis spectrophotometer (Agilient Technologies). All mea-
surements were performed in triplicate and repeated once to
ensure reproducibility.3 | RESULTS AND DISCUSSION
In this study we investigated whether there was an enantio-
meric difference in antimicrobial activity of both mononu-
clear and binuclear dppz‐ruthenium(II)‐centered complexes
with phen as the peripheral ligands, and the plausible mode
of action for their antimicrobial effect.
Neither ΔΔ‐ nor ΛΛbiRu‐phen showed any significant
antimicrobial activity against either bacterial strain, and no
716 MÅRTENSSON ET AL.enantiomeric difference could be observed. The sudden drop
in bacterial growth at the highest complex concentrations
could be caused by lysis of the cellular membrane, and not
by interaction with DNA. To verify this hypothesis, we
exposed microbial cells to the highest concentration of
binuclear complexes and quantified the release of nucleic
acids. During 60 min of biRu‐phen exposure the optical
density at 260 nm of cell‐free filtrates increased for both
B. subtilis and E. coli, indicating nucleotide leakage (see
Fig. S2 in the Supporting Information). Notably, the leakage
of nucleic acid material was similar for the binuclear com-
plexes and a 3% SDS solution, indicating a similar effect of
the metal complexes and the detergent. The more gradual
OD260 increase in E. coli compared to B. subtilis was mostTABLE 1 MIC and MBC valuesa
Compound B. subtilis E. coli
MIC MBC MIC MBC
Δ 8 16 32 > 400
Λ 16 32 128 > 400
Δ Δ NDb 150 NDb 300
Λ Λ NDb 150 NDb 300
Tetracycline 8 16 < 1 < 1
aMIC and MBC values indicated as μM. (Ru‐phen: 1 μM = 0.82 μg/ml; biRu‐
phen: 1 μM = 1.63 μg/ml; Tetracycline hydrochloride: 1 μM = 0.48 μg/ml).
bNot determined due to the ruthenium complex precipitating in the LB medium.
(A)
(C)
FIGURE 1 Surviving bacterial counts (CFU/mL) of B. subtilis (left column) and
phen (bottom row, c,d) at 37°C. Each point is the mean of six replicate cultures. Er
small as or smaller than the symbols plottedlikely caused by the less‐permeable outer membrane charac-
teristic of Gram‐negative bacteria.39 No enantiomeric differ-
ence was observed. As bacterial membranes have a higher
proportion of negatively charged phospholipids compared
with eukaryotic cells, as well as negatively charged teichoic
acid and lipopolysaccharides,40–42 it is not surprising that
the large binuclear ruthenium complex with a 4+ cationic
charge would preferentially bind to the outer membrane of
the bacterial cell.
Table 1 shows a summary of determined MIC and MBC
values. The lowest MIC value was observed with ΔRu‐phen
against B. subtilis, with an inhibitory effect comparable to
that of tetracycline against the same bacteria. In contrast,
ΛRu‐phen was less effective, with a 2‐fold increase in its
MIC value. The enantiomeric difference in Ru‐phen was even
higher when tested against E. coli, with Λ requiring an 4‐fold
higher concentration for the same bacteriostatic effect as Δ,
but with an overall weaker inhibitory effect compared with
B. subtilis.
In order to determine the MBC values for both ruthenium
complexes a series of spot plating was performed (Figure 1
[SD: 3σ] and Table 1). E. coli was never fully eradicated even
with the highest concentrations tested. However, both Δ‐ and
ΛRu‐phen showed a high bactericidal effect in B. subtilis,
with a 2‐fold higher efficiency in Δ compared to Λ. We also
observed a plateau for the viability of E. coli at increasing(B)
(D)
E. coli (right column) after 24‐h exposure to Ru‐phen (top row, a,b) and biRu‐
ror bars show standard deviations (SD: 3σ); when not visible, these bars are as
(A)
(B)
FIGURE 2 Normalized emission spectra of bacterial cells. (a) B. subtilis;
(b) E. coli after overnight exposure to ruthenium complex (40 μM) at 37°C.
The cells were washed twice and resuspended in 1× PBS solution. Emission
from bacterial cells without exposure has been deducted. Black: ΔRu‐phen;
red: ΛRu‐phen; black dot: ΔΔbiRu‐phen; gray dash: ΛΛbiRu‐phen
MÅRTENSSON ET AL. 717concentrations of the mononuclear complexes (Figure 1b)
before a sudden drop to almost zero bacterial growth. A
similar yet much less pronounced effect can be seen for
the binuclear complexes (Figure 1d). This response is
likely the effect the emergence of a small subpopulation
bacteria (so called “persisters”) that is able to survive
antimicrobial exposure, and is part of a survival strategy
already well established in E. coli.43–45 The slow‐growing
persister cells emerge as a response to environmental
triggers such as antibiotics and acts as an insurance for
the general bacterial population to survive in a stressful
environment.
It is conceivable that DNA, being chiral due to its right‐
handed helical structure, would interact differently with the
disymmeric nonintercalating peripheral pair of phen ligands
on the ruthenium complex depending on chirality. Being
either right‐ or left‐handed, the Δ‐ and Λ‐forms should fit dif-
ferently into the grooves of the DNA. This could be observed
in the early experiments with [Ru(phen)3]
2+ where the Δ‐ and
Λ‐forms differed in their individual binding modes with
DNA17,46,47 and was further supported in studies with the
intercalating analog Ru‐phen, where ΔRu‐phen was deter-
mined to have a stronger binding affinity (2–5 times) for
DNA compared to the Λ‐form.48,49 The same chiral discrim-
ination was observed in this study, with ΔRu‐phen showing
both stronger bacteriostatic effect against both B. subtilis
and E. coli compared to the Λ‐form, indicating DNA binding
as the primary antimicrobial mode of action. To test this
hypothesis, emission of the bacterial cells was recorded after
an overnight incubation with the ruthenium complexes. The
bacterial cells were exposed to an excess of ruthenium com-
plex, as indicated by the yellow color of the supernatants after
washing. No emission of the supernatants was observed, thus
suggesting that the cellular membranes of the bacteria had
remained intact. Both Ru‐phen and biRu‐phen are known as
“light‐switch complexes,” meaning that they are completely
quenched when unbound in aqueous solution, but show
intense fluorescence when intercalated to DNA. Therefore,
any fluorescence observed would suggest DNA binding. In
both strains, the intensity of emission from the bacterial cells
after incubation with ΔRu‐phen was significantly higher than
that of the Λ‐form (Figure 2). A slight redshift was observed
for ΛRu‐phen in both strains, a phenomenon associated with
DNA‐complex interactions.35,50 The largest difference was
observed in E. coli, consistent with the results from the metal
susceptibility assays. The smaller difference in emission for
cells of B. subtilis exposed to ΔRu‐phen or ΛRu‐phen could
depend on the base composition of the genome. The genome
of B. subtilis has a higher content of the A and T nucleic acids
(56.5%)51 compared to the genome of E. coli (49.2%),52 and
therefore could explain the less profound difference in inten-
sities, in accordance with the early work by Hiort et al., where
the same relative intensities were observed to differ less
between Δ‐ and Λ‐[Ru(phen)2dppz]2+ when bound to AT‐
sequences compared to calf thymus DNA.35 No emission inthe binuclear complex was observed, indicating no interac-
tion with DNA.
Figure 3 shows a confocal microscopic picture of
Hoechst‐stained E. coli that had been previously treated with
either enantiomer of Ru‐phen. The figure clearly shows emis-
sion from both enantiomers, but with much higher intensity
from the Δ‐form. In addition, the relation between the inten-
sity of the Hoechst stain and the intensity of the complex
appears to be inverse; the cells with the highest intensity of
ruthenium complex appears to have very weak if any fluores-
cence from the Hoechst staining, and vice versa. This relation
is apparent for both enantiomers. The ruthenium complex and
the DNA‐stain compete for binding in the minor groove of
DNA, thus explaining why bacterial cells with high signal
for Ru‐phen have poor emission from the DNA‐stain due to
saturation on binding sites on the DNA. The same effect
could be observed in B. subtilis, while the enantiomeric dif-
ference in emission was not as distinct (shown in Figure S3
in the Supporting Information). Furthermore, unexposed
FIGURE 3 Confocal microscopy images of
formaldehyde fixed E. coli samples incubated
with Δ‐ (top row) and ΛRu‐phen (middle row)
overnight and then stained with Hoechst 33342.
(a) fluorescence, Hoechst 33342 (Δ‐sample); (b)
fluorescence, ΔRu‐phen; (c) fluorescence,
Hoechst 33342 (Λ‐sample); (d) fluorescence,
ΛRu‐phen; (e) fluorescence, control sample E. coli
stained with Hoechst 33342 (Bottom right: a black
square for visual aid). Scale bar =5 μm
718 MÅRTENSSON ET AL.bacterial cells used as controls showed significantly stronger
emission from the Hoechst dye compared to bacteria exposed
to ruthenium complex, again indicating that ruthenium com-
plex and the DNA binding dye competes for the same binding
sites.
In conclusion, this is the first reported work of the poten-
tial usage of enantiopure [Ru(phen)2dppz]
2+ and [μ‐
bidppz(phen)4Ru2]
4+ as antimicrobial compounds. While
the binuclear complex had no major toxic effect on bacterial
cells, the mononuclear complex showed a high antimicrobial
activity, especially in B. subtilis, where the effect was compa-
rable to that of tetracycline (as given in Table 1). Importantly,
we observed the Δ‐enantiomer of [Ru(phen)2dppz]2+ to be 2‐
fold more effective in both inhibiting and killing B. subtilis in
comparison to the Λ‐enantiomer. Our initial results suggest
diastereomeric DNA interactions as the antimicrobial mode
of action, which was further supported by stronger emissionfrom Δ compared with Λ in bacterial cells exposed to the
compounds. This study clearly demonstrates the potential of
enantioselectivity in the bactericidal action of substitution
inert transition metal complexes, and emphasizes the impor-
tance of studying enantiopure compounds.4 | CONCLUSION
Two ruthenium(II) polypyridyl complexes were tested
for their antimicrobial activity: [Ru(phen)2dppz]
2+ and
[μ‐bidppz(phen)4Ru2]4+, both resolved into their pure enan-
tiomeric forms (Δ and Λ). Both enantiomers of [Ru(phen)2
dppz]2+ displayed high bactericidal effect against Gram‐posi-
tive B. subtilis, comparable to the antimicrobial activity of
tetracycline, while having a more bacteriostatic effect on
Gram‐negative E. coli. In contrast, [μ‐bidppz(phen)4Ru2]4+
MÅRTENSSON ET AL. 719showed significantly lower antimicrobial activity against both
bacterial strains with a bactericidal effect only at the highest
concentrations tested.
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